Adalvo is thrilled to announce that we have successfully completed our Pivotal BE program for Empagliflozin 25mg film-coated tablets. This product has been developed in collaboration with one of our strategic partners.
Our product has been developed based on the reference brand Jardiance 25mg film-coated Tablets, which is indicated in the treatment of type 2 diabetes mellitus.
The brand sold approximately $14bn globally in 2022, having a significant growth potential with Global 3Y CAGR at +26%, according to IQVIA.
Based on this successful development, we expect be amongst the first companies to launch on Day-1, in all major markets.
Adalvo is one of the few companies having an extensive offering of both small molecule and peptide treatment possibilities for type 2 diabetes, as depicted below.
Partner Up Now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force